ATLASIambic Therapeutics, Inc. IPO (IAM)
The data feed lists Iambic Therapeutics, Inc. for NASDAQ with a start date of Oct 15, 2026, status "Priced", and an offer price of $16.00 (original range $15.00 to $17.00) per the final prospectus (424B4). First-day change from open to close: +17.1%.
Updated November 4, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
Iambic Therapeutics is a technology and clinical-stage life sciences company that integrates large-scale artificial intelligence with automated, scalable chemistry and biology experimentation—an approach it calls molecular superintelligence—to discover and develop small-molecule drug candidates. The company is based in the United States and was founded in October 2019. Its most advanced program, IAM1363, is an oral HER2 inhibitor in a Phase 1/1b clinical trial; additional candidates IAM217 and IAM-C1 are in earlier stages. The company has generated collaboration revenue from partners including AbbVie, Takeda, Lundbeck, and others, but has no products approved for commercial sale.
The offer
- Offer price
- $16.00
- Original range
- $15.00 - $17.00
- Shares offered
- 9,375,000
- Over-allotment option
- 1,406,250 shares
- Gross proceeds
- $150,000,000
- Net proceeds to the company
- $135.0M ($155.9M with full option)
- Shares outstanding after the offering
- 38,025,796
- Lead underwriters
- J.P. Morgan, Jefferies, BofA Securities, Citigroup
- Lock-up
- 180 days
Use of proceeds
The company intends to use the net proceeds, together with existing cash and cash equivalents, to advance the clinical development of IAM1363, IAM217, and IAM-C1 through various trial phases, to continue investing in its molecular superintelligence platform, and the remainder, if any, for working capital and other general corporate purposes. A portion may also be used to acquire or invest in businesses, products, services, or technologies.
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Revenue | 1,194 | 9,426 | 3,928 | 12,753 |
| Net income (loss) | -47,877 | -77,295 | -33,165 | -50,116 |
| Cash and equivalents | 207,878 | — | — | 207,878 |
| Total assets | — | — | — | 237,196 |
Key risks
Limited operating history. Iambic is a technology and clinical-stage life sciences company with a limited operating history, no products approved for commercial sale, and no revenue from product sales, which may make it difficult to evaluate prospects and predict future success.
Platform unproven, no approved drugs. The company's molecular superintelligence approach is novel and unproven, in that it has not yet led to an approved drug product to date, and there is no guarantee that the platform will lead to successful clinical trials or approval of product candidates.
Need for additional capital. The company has generated losses since inception, including a net loss of $77,295 thousand for the year ended December 31, 2025, and an accumulated deficit of $245,296 thousand as of June 30, 2026, and will need additional capital to fund operations.
Stock price volatility and lock-up releases. The market price of the company's common stock may fluctuate significantly due to factors including sales of shares by insiders or stockholders and the anticipation of lock-up releases or expiration of market standoff or lock-up agreements.
No products generating revenue. Since its inception in October 2019, the company has focused substantially all efforts on building its platform and has no products approved for commercial sale and has not generated any revenue from product sales.
Timeline
- Sep 21, 2026 · Registration statement filed (S-1)
- Oct 8, 2026 · Amendment (S-1/A)
- Oct 15, 2026 · Final prospectus (price set) (424B4) View filing
- Oct 16, 2026 · Current report (8-K)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 4, 2026.
Calendar data
| Status in feed | Priced |
|---|---|
| Start date | Oct 15, 2026 |
| Exchange | NASDAQ |
| Shares offered | 9,375,000 |
| First-day change (open to close) | +17.09% |
| First-day open | $16.15 |
| First-day close | $18.91 |
| Filing date | Oct 15, 2026 |
| Last amended | Oct 15, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow IAM and get one email when it starts trading.
Create an accountFrequently asked questions
What does Iambic Therapeutics, Inc. do?
Iambic Therapeutics is a technology and clinical-stage life sciences company that integrates large-scale artificial intelligence with automated, scalable chemistry and biology experimentation—an approach it calls molecular superintelligence—to discover and develop small-molecule drug candidates. The company is based in the United States and was founded in October 2019. Its most advanced program, IAM1363, is an oral HER2 inhibitor in a Phase 1/1b clinical trial; additional candidates IAM217 and IAM-C1 are in earlier stages. The company has generated collaboration revenue from partners including AbbVie, Takeda, Lundbeck, and others, but has no products approved for commercial sale.
How much is the Iambic Therapeutics, Inc. IPO raising?
The final prospectus sets a price of $16.00 per share for 9,375,000 shares, or $150,000,000 before expenses and discounts.
Who are the underwriters of the Iambic Therapeutics, Inc. IPO?
J.P. Morgan, Jefferies, BofA Securities, Citigroup.
When is the Iambic Therapeutics, Inc. IPO?
The data feed lists a start date of Oct 15, 2026 with status "Priced".
What is the Iambic Therapeutics, Inc. IPO price range?
According to the final prospectus (424B4), the offer price is $16.00 per share and the original range was $15.00 to $17.00.
How is the first-day change measured?
On the first trading day (Oct 15, 2026) the stock moved +17.09% from its open ($16.15) to its close ($18.91), from daily price data. This is not the change from the IPO offer price.
What does "Priced" mean?
The feed reports the offering as priced. The start date is the first trading day.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer